RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS
Clinical trials for RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS explained in plain language.
Never miss a new study
Get alerted when new RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS trials appear
Sign up with your email to follow new studies for RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New TB drug could cut treatment time by two months
Disease control Recruiting nowThis study tests whether a new drug called quabodepistat can shorten treatment for drug-resistant tuberculosis (TB) from 6 months to 4 months. About 532 adults and teens with rifampicin-resistant or multidrug-resistant TB will be randomly assigned to receive either the new shorte…
Matched conditions: RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New 2-Month TB pill cocktail could replace 6-Month regimen
Disease control Recruiting nowThis study tests a new ultra-short treatment for both drug-sensitive and drug-resistant tuberculosis (TB). The goal is to see if a 2-3 month regimen works as well as or better than the standard 4-6 month treatment. About 610 adults with active TB will take part. The approach coul…
Matched conditions: RIFAMPICIN-RESISTANT PULMONARY TUBERCULOSIS
Phase: PHASE3 • Sponsor: Shenzhen Third People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC